Helius Medical Technologies Achieves Nasdaq Compliance Status
In recent developments, Helius Medical Technologies, Inc. (Nasdaq: HSDT), based in Newtown, Pennsylvania, has made remarkable strides in meeting the compliance requirements set forth by the Nasdaq stock exchange. As a pioneer in neurotechnology, Helius focuses on enhancing therapeutic solutions for individuals suffering from balance and gait impairments.
Recent Achievements in Compliance
On July 7, 2025, Helius received an official notice from the Nasdaq Hearings Panel confirming that the company has fulfilled the necessary criteria under the Equity Rule, which is crucial for maintaining its listing on the Nasdaq Capital Market. This compliance is a testament to Helius's commitment to adhering to financial regulations and practices.
Furthermore, prior to this notification, on June 3, 2025, Helius had successfully demonstrated compliance with the minimum bid price requirement established by Nasdaq Marketplace Rule. This achievement allows the company to continue operating in a competitive environment on one of the leading stock exchanges.
Mandatory Monitoring Period
In accordance with the Nasdaq rules, Helius will be under a Mandatory Panel Monitor for one year following this confirmation of compliance. This entails ongoing evaluations to ensure that the company remains in good standing within the market.
Innovative Solutions from Helius Medical Technologies
Helius Medical Technologies is dedicated to addressing neurological deficits through its innovative Portable Neuromodulation Stimulator. This groundbreaking device has garnered attention for its effectiveness in helping individuals with neurologic conditions enhance their physiological capabilities and foster neuroplasticity.
Through the application of a unique orally applied technology platform, Helius aims to amplify the brain's natural ability to compensate for deficits in balance and gait. Such advancements promise improved quality of life for those affected by various neurologic disorders.
Company Vision and Future Prospects
Looking ahead, Helius Medical Technologies is poised to expand its reach and influence in the neurotech sector. By continually innovating and developing cutting-edge products, the company is determined to lead the charge in the treatment of neurologic diseases, striving for better outcomes and enhanced patient care.
Contact Information for Investor Inquiries
For those interested in further information or investment opportunities, Helius encourages direct contact with its Investor Relations team. Philip Trip Taylor of the Gilmartin Group can be reached for inquiries, ensuring potential and current investors stay informed.
In summary, Helius Medical Technologies stands firm in its mission to enhance neurological health through innovative technologies while maintaining compliance and fostering market growth.
Frequently Asked Questions
What recent compliance achievement did Helius Medical Technologies attain?
Helius Medical Technologies received confirmation from Nasdaq that it complies with their equity requirements for continued listing.
What is the main product offered by Helius Medical Technologies?
The company's flagship product is the Portable Neuromodulation Stimulator, aimed at assisting individuals with neurologic deficits.
How long will Helius be under mandatory monitoring by Nasdaq?
Helius will be subject to a Mandatory Panel Monitor for one year following their recent compliance confirmation.
What does the technology platform from Helius do?
Helius's platform amplifies the brain's ability to promote neuroplasticity and engage compensatory mechanisms in individuals with balance and gait deficits.
Who can investors contact for more information about Helius?
Investors can reach out to Philip Trip Taylor from the Gilmartin Group for further inquiries regarding Helius Medical Technologies.
